Lists of funding opportunities are updated weekly. New funding opportunities for scientists are distributed in the VPRI Update newsletter.
To submit funding opportunities, and/or be added to the VPRI Update mailing list, please send your request to VPRI@smh.ca.
Opportunities are categorized by Sponsor Type (Tri-Agency, Other Canadian, International & NIH). Filter opportunities by keyword (e.g. Sponsor Type, CIHR, user-supplied keyword, etc.) using the Search box at right.
|Sponsor Type||Funding Program Title||Amount and Duration||Description||Deadline|
|Tri-Agency||CIHR Catalyst Grant: Quadruple Aim and Equity||Up to $100,000 for 1 year.||The Quadruple Aim is centred on four overarching goals to redesign health care systems: improve the patient experience of care; improve the health of populations; improve the health care provider experience; and improve value for money. This opportunity supports one-year knowledge creation and knowledge implementation projects, grounded in an integrated knowledge translation (iKT) approach, (i.e., where knowledge users are engaged in the entire research process).||October 26, 2021.|
|Tri-Agency||CIHR Pre-Announcement: Indigenous Peoples and COVID-19||Research Operating Grants: Up to $250,000 for one year; Knowledge Mobilization Grants: Up to $150,000 for one year.||This funding opportunity will provide funding for research and knowledge mobilization for Indigenous communities (i.e., First Nations, Inuit, Métis and/or Urban Indigenous communities), Indigenous organizations and researchers who identify as Indigenous (or researchers who provide evidence of having meaningful and culturally safe involvement with Indigenous Peoples) in Canada who are responding to the unique health and well-being needs of Indigenous Peoples as they relate to the COVID-19 pandemic.||Launch: Week of October 11, 2021.
Registration Deadline: Week of November 8, 2021.
Application Deadline: Week of December 6, 2021.
|Tri-Agency||CIHR Operating Grant: Indigenous COVID-19 Rapid Research Funding Opportunity||Research Operating Grants: Up to $250,000 for one year|
Knowledge Mobilization Grants: Up to $150,000 for one year.
|This funding opportunity will provide funding for research and knowledge mobilization for Indigenous communities (i.e., First Nations, Inuit, Métis and/or Urban Indigenous communities), Indigenous organizations and researchers who identify as Indigenous (or researchers who provide evidence of having meaningful and culturally safe involvement with Indigenous Peoples) in Canada who are responding to the unique health and well-being needs of Indigenous Peoples as they relate to the COVID-19 pandemic.||Registration: November 9, 2021.
Application Deadline: December 7, 2021.
|Tri-Agency||CIHR Other: SPOR Networks - Knowledge Mobilization and Implementation Science||Up to $3,750,000 over 4 years.||This funding opportunity supports the SPOR Chronic Disease Networks to:|
- Conduct patient-oriented research with a focus on implementation science;
- Mobilize and apply knowledge generated through patient-oriented research to improve healthcare systems and practices, and ultimately, contribute to equitable health outcomes;
- Support patient-oriented research capacity building and partnerships.
The Nominated Principal Applicant (NPA) must be a Principal Investigator of one of the following SPOR Chronic Disease Networks: CHILD-BRIGHT, Chronic Pain Network, Diabetes Action Canada, IMAGINE-SPOR, Can-SOLVE CKD.
|November 11, 2021.
|Tri-Agency||SSHRC Race, Gender and Diversity Initiative||Up to $450,000 for up to 3 years.||This will support community-based and community-led research, carried out in partnership with postsecondary institutions, that is based on the lived experience of underrepresented and disadvantaged groups, including but not limited to women; First Nations, Inuit and Métis Peoples; Black, Asian and other racialized peoples; people living with disabilities (both visible and invisible); LGBTQ2+ people; religious minorities; and others marginalized on the basis of their ethnicity and other identity factors, as well as individuals who identify as, or belong to, more than one of these groups.||November 15, 2021.|
|Tri-Agency||SSHRC Open Research Area for the Social Sciences Seventh Call for Proposals 2021||From SSHRC, up to $135,000 per year for 2 or 3 years, to a maximum of $400,000.||This funds integrated joint research projects in social sciences by researchers in at least three of the four subscribing countries, Canada, France, Germany and the UK. In addition, there is the potential for collaboration by a Japanese team. Proposals may be submitted in any area of the social sciences. However, the disciplinary coverage varies according to the involvement of the national agencies. Canadian researchers are invited to submit proposals in any discipline or subject area eligible for SSHRC funding.||November 17, 2021.|
|Tri-Agency||CIHR Operating Grant: Cannabis Research in Longitudinal Studies||Up to $100,000 per year for up to 5 years for Existing Studies; Up to $150,000 per year for 5 years for New Studies.||This will support projects relevant to the following research areas:|
- Existing Longitudinal Studies: Collection and analysis of measures relevant to cannabis research in existing longitudinal studies within IHDCYH's mandate are or within INMHAs mandate area.
- New Longitudinal Study on Cannabis Use in Veterans: Development of a new prospective longitudinal cohort observational study to examine the benefits and harms of medically authorized cannabis use in Canadian Armed Forces Veterans, including symptoms of cannabis use disorder.
December 1, 2021.
January 12, 2022.
|Tri-Agency||CIHR Operating Grant: Summer Program in Aging - Planning Grant||$100,000.00||This provides a planning grant to host the 2023 CIHR Institute of Aging's Summer Program in Aging (SPA). It provides funding to develop and implement an intensive capacity-building program on the topic 'Oldest Old'. The host of SPA 2023 will:|
- Develop the program and curriculum for an advanced training program for graduate students and postdoctoral fellows that crosses disciplines, sectors, institutions and geography
- Recruit and lead a planning and coordination team for SPA 2023
- Coordinate and manage the logistics related to the successful implementation of the SPA 2023 program
|December 7, 2021.|
|Tri-Agency||CIHR Other: SPOR Primary Care Network||$10,000,000 over 5 years.||The specific objectives of this funding opportunity are to support a national Network that will: |
- Facilitate, through research and partnerships, the increase in reach, adaptation, and accessibility of successful patient-oriented primary and integrated health care innovations to new sites, new settings, and/or new populations;
- Mobilize knowledge generated to inform and transform practice, clinical care, policy, and/or decision making toward optimal and equitable health outcomes;
- Build capacity for the ongoing application of patient-oriented primary and integrated health care knowledge.
The applicant team must include a minimum of two individuals who self-identify as Indigenous (First Nations, Métis and Inuit, including members of Urban Indigenous communities).
|December 7, 2021.|
|Tri-Agency||SSHRC Partnership Engage Grants||$7,000 to $25,000 for 1 year||Partnership Engage Grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector. The small-scale, stakeholder-driven partnerships supported through the Partnership Engage Grants are meant to respond to immediate needs and time constraints facing organizations in non-academic sectors.||December 15, 2021.|
|Tri-Agency||CIHR Team Grant: Transitions in Care (TiC) - Phase 2||Up to $240,000 per year for up to 4 years.||This will support inter-disciplinary teams that are poised and ready to optimize health outcomes during transitions in care. The grants will provide support to develop, implement, evaluate, and equitably spread and/or scale (share) pragmatic solutions to challenges associated with transitions in care from a clinical, health care or health system perspective. Applicants are required to have a health system partner.||January 25, 2022.|
|Tri-Agency||SSHRC Partnership Grants Stage 1||Up to $20,000. Stage 2: Up to $500,000 per year over 4-7 years, up to a total of $2,500,000.||Partnership Grants are intended for large teams working in formal collaboration between postsecondary institutions and/or organizations from the public, private and/or not-for-profit sectors. Funds are available to support a variety of formal partnership initiatives, e.g. disciplinary, interdisciplinary, inter-institutional, international and/or cross-sectoral, in any of the disciplines and themes eligible for funding at SSHRC.||Stage 1: February 10, 2022.
Stage 2 (by invitation only): TBD.
|Tri-Agency||CIHR Team Grant: Indigenous Healthy Life Trajectories Initiative Cohort Research Study (I-HeLTI)||Research Grant: Up to $2,000,000 per year for up to 6 years; Collaborating Centre: Up to $350,000 per year for up to 6 years.||This funding opportunity will support projects relevant to the following research areas:|
An I-HeLTI Intervention Cohort Research Study that will encompass the continuum of care and prevention of non-communicable diseases, from preconception to pregnancy, infancy and early childhood with a life trajectory perspective. An I-HeLTI Collaborating Centre that will steward the emerging I-HeLTI cohort, governance processes and data management. Eligibility to apply to this funding opportunity is limited to the three CIHR-funded I-HeLTI research teams.
|June 6, 2022.|
|Tri-Agency||NSERC Alliance/Mitacs Accelerate Grants||--||This is for applicants seeking support from both an Alliance grant and Mitacs Accelerate, to apply through a single application submission and review process. Applicants who wish to include Mitacs Accelerate internships in their Alliance application should contact their local Mitacs business development representative to obtain the NSERC/Mitacs joint application form.||Ongoing|
|Tri-Agency||NSERC Alliance Grants||$20,000 to $1 million per year for 1-5 years||Support university researchers to collaborate with partner organizations, which can be from the private, public or not-for-profit sectors.|
NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office.
|Other Canadian||Cystic Fibrosis Canada (CFC): 2021-2022 Grants|
Early Career Investigator Awards: Up to $100,000 per year for 1 or 2 years.
Early Career Investigator Awards: This provides investigators who are early in their career establishment grant funds to develop and demonstrate their independence for initiating and conducting outstanding cystic fibrosis research. For the 2021 competition, an early career investigator is an independent researcher who has held their first full-time academic or research appointment for no longer than 84 months at the time of applying.
Early Career Investigator Awards: Full Application: November 1, 2021.
|Other Canadian||Canadian Institute for Advanced Research (CIFAR): Azrieli Global Scholars Program||$100,000 for 2 years.||This accelerates the development of the next generation of research leaders and positions them to heighten their impact in academia and beyond. Applicants must hold a PhD (or equivalent) and be within the first five years of starting a full-time research position at an institution of higher education or research. This year, CIFAR invites applications for the following CIFAR research programs: Bio-inspired Solar Energy, Child & Brain Development, Gravity & the Extreme Universe, Learning in Machines & Brains, Quantum Information Science, and Quantum Materials.||October 27, 2021.|
|Other Canadian||Genome Canada Genomic Applications Partnership Program (GAPP):|
Total project size $300,000 to $6 million for 2-3 years.
|This funds downstream research and development (R&D) projects that address real-world opportunities and challenges defined by "Receptor" organizations such as industry, government, or not-for-profit entities. These projects are co-funded by Receptors and other stakeholders and must have the potential to generate significant social and/or economic benefits for Canada. Please contact Ann Meyer, Advisor, Sector Innovation & Programs, (ameyer@OntarioGenomics.ca) with any questions and/or to initiate your application process.||November 3, 2021.|
|Other Canadian||Canadian Blood Services (CBS) BloodTechNet Award Program:|
Up to $50,000 for up to 1 year.
|This supports the development of innovative educational projects that network the Transfusion, Cellular Therapy and Transplantation communities in Canada. These projects deliver educational tools and resources that support the development of skills, knowledge and expertise of the health professionals in this network. The BloodTechNet Award Program is targeted towards medical lab technologists, nurses and physicians.||November 15, 2021.|
|Other Canadian||CAAIF-Avir Pharma Early Investigator Research Grant in Eosinophilic Esophagitis:|
Up to $10,000 for up to 12 months.
|This is to support early career investigators doing research relevant to Eosinophilic Esophagitis (EoE). Applicants must be within the first 7 years of completing their degree and/or training.||November 15, 2021.|
|Other Canadian||Internal Call for Tier 2 Canada Research Chair (CRC) at Unity Health Toronto|
Up to $10,000 for up to 12 months.
|Unity Health Toronto has launched an an internal call for a Tier 2 CRC, whose work is aligned with one or more of our four established pillars of world class research and innovation. In order to address the underrepresentation of members of the four designated groups (women, members of visible minorities, persons with disabilities, and Indigenous peoples) in the CRC Program, and to ensure that the members of these groups will not be under-represented among Chair holders across the University of Toronto and it affiliated hospitals, this special call is open only to individuals who self-identify as members of at least one of these four designated groups. All applicants who applied for the CRC Call for Nominations in July 2021, will automatically be considered. Past applicants have the option to submit updated materials (although not required). For more information, see the website or contact Erica.Conte@unityhealth.to.||Submit nominations (or updated material) to VPRI@smh.ca by November 15th, 2021. Separately, send the CRC self-identification form directly to Erica.Conte@unityhealth.to.|
|Other Canadian||Novo Nordisk-BBDC Pilot and Feasibility Grants 2022/2023||$40,000 per application.||This program is to explore new diabetes research initiatives in the area of biomedical research/basic sciences. It is not intended to support activities in diabetes care delivery, evaluation of diabetes education programs, or practical issues in diabetes management. The principal applicant must be a registered member of the BBDC at the time of application submission.||November 18, 2021.
|Other Canadian||TRANSFORM HF Seed Grants: Call for Applications||$50,000 for 1 year.||The focus themes are: 1) Equity, diversity, accessibility, and inclusion in heart failure; 2) Data science innovation in heart failure prevention, treatment, or care; 3) Digital health (including virtual health, point-of-care testing, implantables, sensors, wearables, and apps) and heart failure. Applicants must be investigators affiliated with TRANSFORM HF and the University of Toronto and/or the institutions within the Toronto Academic Health Sciences Network.||November 29, 2021.
|Other Canadian||Canadian Hemophilia Society (CHS) Various Opportunities||CHS Dream of a Cure Research Program:$75,000 per year (Maximum $150,000 over 2 or 3 years)|
CHS/Pfizer Care Until Cure Research Program: $75,000 per year (Maximum $150,000 over 2 or 3 years)
CHS/Novo Nordisk Canada Psychosocial Research Program: Maximum of $40,000 for 1 year.
CHS - Bayer - ADVANCE Canada Research Program: Maximum of $60,000 for 2 year.
|CHS Dream of a Cure Research Program: Supports research focused on improving the health and the quality of life of all people with inherited bleeding disorders and finding a cure. The CHS invites applicants to apply for basic scientific research grants in fields relevant to hemophilia A and B, von Willebrand disease, rare factor deficiencies, platelet function disorders (and platelet pathophysiology) and other congenital and acquired bleeding disorders. |
CHS/Pfizer Care Until Cure Research Program: Supports medical and psychosocial aspects of bleeding disorders, including outcome evaluation. Grants are awarded for clinical research in fields relevant to improving the quality of life for persons with hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C, and carriers of an inherited bleeding disorder. Please see website for the specific areas of interest for the 2022-2023 granting period.
CHS/Novo Nordisk Canada Psychosocial Research Program: This program was created to engage professionals/graduate students from the allied health disciplines (i.e. Nursing, Physiotherapy & Social Work) in research activities addressed to understanding the psychosocial impact of hemophilia and other inherited bleeding disorders and to improve the quality of life of persons and families whose lives are affected by these disorders.
CHS - Bayer - ADVANCE Canada Research Program: This program was created to engage Canadian hemophilia treaters in activities to identify and research key issues in the ageing hemophilia population. In order to optimize management of age-related co-morbidities in the adult hemophilia population, ADVANCE Canada will foster patient-centred research, and disseminate scientific information to assist Canadian hemophilia-treating physicians.
|December 10, 2021.|
|Other Canadian||Canadian Orthopaedic Foundation: Various Opportunities||J. Édouard Samson Award:$30,000 for 2 years. Includes an educational grant and a personal research grant to be used by the recipient at the Canadian institution where he/she currently resides. |
CORL - Canadian Orthopaedic Research Legacy Grant:Up to $20,000 for 1-2 years
|J. Édouard Samson Award:This recognizes the best career orthopaedic research over a period of five (5) years or more at a Canadian centre. |
CORL - Canadian Orthopaedic Research Legacy Grant:This is to help ensure the legacy of Canadas world-class status in orthopaedic research, thereby ensuring orthopaedic patients reap the reward of new techniques and treatments made possible through research grants from this program.
|December 17, 2021.
|Other Canadian||Important Notice to New Frontiers in Research Fund (NFRF) Applicants||--||Submissions for all stages of all NFRF competitions must be submitted by no later than 10:00AM on the day of the deadline. This internal deadline is mandatory in order for ORA to approve the submission and forward it to NFRF.||--|
|Other Canadian||Mitacs Accelerate: Eligibility and New Program Updates||--||Options and enhancements include expanding eligibility for both interns and external sponsoring partners, and increasing support levels for some partners.|
Mitacs Accelerate-Expanded Eligibility Criteria: Mitacs can now support undergraduate students as interns on a Mitacs Accelerate grant. In addition, municipalities and hospitals are now considered to be eligible partner organizations for Mitacs Accelerate
Mitacs SME Discount Model:Until February 1, 2022, a partner organization that is a small/medium-sized enterprise (SME) in the for-profit or non-profit sector will only be charged 25% of the overall project costs instead of Mitacs's typical 50% cost-sharing ratio. Details here: Link.
Accelerate Industrial Post-Doctoral Fellowship-New Funding Model: This funding stream provides $60,000/year for a post-doctoral fellow, where the partner organization must contribute $30,000 plus applicable taxes per year. Details here: Link.
Mitacs and National Research Council (NRC) collaborative funding stream for R&D projects: Support for 250 graduate and post-graduate student internships within the NRC's Challenge and Supercluster support programs. Details here: Link.
|Other Canadian||New Mitacs Initiatives and Opportunities||--||Mitacs Parterships with Municipalities: Professors, postdoctoral fellows, graduate students, college students and undergraduate students can now put their talent to work on a collaborative research project at a municipality that needs your expertise. Canadian municipalities of all sizes are now eligible partners for co-funded projects involving post-secondary researchers through Mitacs programs. Details here: Link.|
Mitacs Partnerships with Hospitals: This initiative empowers Canadian hospitals no matter the size, by providing access to the brightest post-secondary researchers and funding for innovative projects. Whether you are a hospital administrator looking to collaborate with experts across a myriad of disciplines or an academic whose research could benefit a hospital, Mitacs can help. Details here: Link.
Indigenous Pathways Initiative: Projects are a minimum of four months in duration - they can be longer - and now Indigenous-owned businesses and organizations contribution is only 25% of the cost of projects that have an Indigenous partner organization and/or an intern who is Indigenous. Details here: Link.
|Other Canadian||Ontario Research Fund - Research Excellence (ORF-RE) Round 11||Stream 1: $500,000 to $2,000,000 for up to 5 years.|
Stream 2: $300,000 to $1,000,000 for up to 4 years.
|This provides research institutions with funding to support the operational costs of major projects of strategic value to the province. The fund provides up to one third of the total value of a project, with the remaining two thirds coming from a combination of private sector and institutional contributions. Round 11 has two application streams:|
- Stream 1: General Basic and Applied Research: Open to all research disciplines.
- Stream 2: Targeted Experimental Research: Funds projects that demonstrate strong commercialization potential, where the innovation is at a Technology Readiness Level (TRL) of 3 or higher. Targeted projects are in the following sectors: information communications technologies; life sciences and medical devices; industrial technologies. Requires collaboration with an Ontario-based company.
|Internal Deadlines: More details will be communicated soon.
Sponsor Deadline: March 21, 2022.
|Other Canadian||University of Toronto Institutional Strategic Initiatives (ISI)||From $50,000-$300,000 per year for up to 3 years.||ISI awards are intended to establish research capacity in high-priority areas, with the goal of realizing transformational impacts on issues of societal importance. Proposed investigator-initiated initiatives must meet the following key criteria: 1) Address a significant challenge and associated research questions that requires an interdisciplinary approach; 2) Matching funds secured from three or more Academic Divisions; 3) Path to sustainability demonstrated by a clear opportunity for external funding.||Ongoing.|
|Other Canadian||Pre-Announcement / Soft Launch: Canada Biomedical Research Fund (CBRF)||--||The CBRF is designed to build on existing assets, infrastructure, partnerships and strengths of institutions, and to support targeted investments for maximum impact. The integrated program delivery features a two-stage competitive process:|
1. selection of three to five research hubs
2. open, national call for proposed partnered research and infrastructure projects associated with the selected research hubs
Research hubs are coalitions of research actors that integrate research organizations, including institutional, not-for-profit, private and/or public organizations.
|Tentative Launch: Fall 2021|
|Other Canadian||Collaboration Opportunities: National Research Council Canada (NRC) Challenge Programs||--||The NRC offers potential opportunities for collaboration in the following areas:|
- Aging in Place
- Artificial Intelligence for Design
- Disruptive Technology Solutions for Cell and Gene Therapy
- High-throughput and Secure Networks
- Pandemic Response
Potential collaborators can register their interest to work with NRC on the Challenge Programs website.
|Other Canadian||Government of Canada: CanExport for Innovators||Maximum of $75,000||Specifically designed to promote and enhance Canada's international innovation efforts. Eligible expenses may include international and local travel, accommodation, meals, meeting costs, legal fees to support formalized partnerships, and other costs related to international collaboration.|
Applications must be submitted at least 8 WEEKS prior to the anticipated start date of the activities.
|Other Canadian||Weston Brain Institute: Early Phase Clinical Trials: Canada||Up to $1,500,000 per project for up to 4 years||Funding for clinical trials and/or clinical trial sub-studies with excellent preliminary data.||Rolling deadline
|Other Canadian||Physicians' Services Incorporated (PSI) Foundation: Health Research Grant & New Investigator Grant||Health Research Grant: Up to $250,000 for 3 years.|
New Investigator Grant: Up to $300,000 for 3 years.
|Areas of Support: clinical research, medical education research, health systems research. Applicant must be a College of Physicians and Surgeons of Ontario licensed MD. New Investigators must be within five years of their first academic appointment.||Rolling deadline|
|Other Canadian||Telus Funds||Various||For entertaining and engaging web series with the potential to positively impact families and friends providing care for loved ones struggling with a health condition.||Various
|Other Canadian||Ontario Centre of Innovation (OCI) Voucher for Innovation and Productivity (VIP) Program||Minimum of $20,000 up to a maximum of $150,000 per year towards the direct costs of research (Industry Partner contribution has to be minimum of 1:1 cash match to the OCE contribution, where at least 50% must be spent at the post-secondary institution.)||This program helps companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario's industry and publicly funded post-secondary institutions and research hospitals. VIP projects are intended to generate economic benefit for companies in Ontario (including job creation/retention, new revenue generation, investment attraction, cost savings, value chain development), in the short-to-medium term (e.g. within three years of project completion).|
If you are interested, please contact Samar Saneinejad (Samar.Saneinejad@unityhealth.to ).
|International||Pfizer Global Medical Grants (GMG) Request for Proposals (RFP): 2021/2022 Global Obesity ASPIRE||Up to USD $250,000 for up to 3 years.||Research in the following areas will be considered: Pathophysiology and biology of overweight and obesity; Understanding Obesity as a disease; Utilizing retrospective databases, generate evidence of optimal management of obesity and co-existing comorbid conditions. Types of research in scope for this RFP are: Basic science, pre-clinical research, and clinical research that aligns with the in-scope research topics; Animal experimentation related to human biology; Physiological, cellular, molecular and translational research.||Letter of Intent: November 5, 2021.
Full Proposal (by invitation): February, 2022.
|International||Foundation Fighting Blindness (FFB): Various Opportunities||Individual Investigator Research Awards (IIRA): USD 100,000 per year up to 3 years.|
Clinical Innovation Awards (CIA): USD 100,000 per year up to 3 years
|Individual Investigator Research Awards (IIRA): These support research in areas with the greatest potential to move toward treatments and cures for the inherited orphan retinal degenerative diseases and dry age-related macular degeneration. |
Clinical Innovation Awards (CIA): These will:(1) develop and apply new technology to measure structure and function in inherited retinal degenerations; (2) establish relationships between measures of retinal functional and retinal structure with the goal of understanding the relationship between genotype and clinical phenotype; (3) identify outcome measures or biomarkers to demonstrate change over a time period spanning no more than 2 to 3 years.
|Letter of Intent: November 5, 2021.
Full Application (by invitation): February 25, 2022.
|International||American Association for Cancer Research (AACR) AACR-Bristol-Myers Squibb Midcareer Female Investigator Grant||USD $225,000 for 3 years.||This supports mid-career female physician-scientists and researchers to conduct immuno-oncology research and to foster their career advancement toward becoming a senior investigator. Research projects may be translational and/or clinical in nature with a focus on immuno-oncology. Applicants must hold an appointment at the rank of Associate Professor. Applicants must be AACR Active members. Nonmembers interested in this grant opportunity must submit a satisfactory application for AACR Active membership by the application deadline.||November 11, 2021.|
|International||American Foundation for Suicide Prevention (AFSP): Grant Cycle 2021-2022|
Distinguished Investigator Innovation Grants: Up to $125,000 over 2 years.
Standard Research Innovation Grants: Up to $100,000 over 2 years.
Young Investigator Innovation Grants: Up to $90,000 over 2 years.
Pilot Innovation Grants: Up to $30,000 over 2 years.
Distinguished Investigator Innovation Grants: For investigators at the level of associate professor or higher with an established record of research and publication on suicide.
Standard Research Innovation Grants: Grants awarded to individual investigators at any level.
Young Investigator Innovation Grants: Grants awarded to investigators at or below the level of assistant professor.
Pilot Innovation Grants: These provide seed funding for new projects that have the potential to lead to larger investigations. These grants typically entail feasibility studies rather than hypothesis-driven research.
Distinguished Investigator Innovation Grants: November 15, 2021.
Standard Research Innovation Grants: November 15, 2021.
Young Investigator Innovation Grants: November 15, 2021.
Pilot Innovation Grants: November 15, 2021.
|International||American College of Surgeons (ACS) Faculty Research Fellowships||USD $40,000 per year for 2 years.||The fellowship is to assist a surgeon in the establishment of their research program under mentorship with the goal of transitioning to becoming an independent investigator. Open to Fellows or Associate Fellows of the College who have: (1) completed the chief residency year or accredited fellowship training within the preceding five years, not including time off for maternity leave, military deployment, or medical leave; and (2) received a full-time faculty appointment in a department of surgery or a surgical specialty.||November 19, 2021.|
|International||Society of American Gastrointestinal Endoscopic Surgeons (SAGES) Research Grants||Up to USD $30,000 for 1 year.||The purpose of these grants is to stimulate original research in gastrointestinal and endoscopic surgery. The study may be either bench research or clinical. Open to any principal investigator who is a current SAGES member, including Candidate Members.||November 19, 2021.|
|International||American Laryngological Association (ALA) Research Grants||American Laryngological Voice and Research Education Grant:USD $10,000 for 12 months.|
Seymour R. Cohen, MD, Research Grant:USD $15,000 for 12 months.
|American Laryngological Voice and Research Education Grant:This supports basic, translational, or clinical research projects in laryngology (voice, airway, swallowing), outcomes, and related subjects, and should lead to furthering the fields of laryngology or neurolaryngology. |
Seymour R. Cohen, MD, Research Grant: Supports basic science research projects in the area of laryngology or neurolaryngology with relevance to the pediatric population, and should lead to furthering the fields of pediatric laryngology or pediatric neurolaryngology.
|Letter of Intent: December 1, 2021.
Complete Application: January 14, 2022.
|International||National Blood Foundation (NBF) Scientific Research Grants Program||Maximum USD $75,000 for 1 year or 2 years.||Grants are awarded to early-stage investigators for investigator-initiated original research in disciplines that impact transfusion medicine, cellular therapies or related sciences. Priority in awarding grants will be given to innovative, new projects. An early-stage investigator is a new investigator who has completed a terminal research degree or medical residency - whichever date is later - within 10 years of the grant application deadline and has not yet been awarded a substantial research grant.||December 1, 2021.|
|International||American Association for the Study of Liver Diseases (AASLD) Various Opportunities||Pinnacle Research Award in Liver Diseases:USD $300,000 over 3 years ($100,000 per year).|
Clinical, Translational and Outcomes Research Award: USD $200,000 over 2 years ($100,000 per year).
Bridge Award: USD $100,000 for 1 year.
Pilot Research Award in Liver Diseases:USD $50,000 for 1 year.
Gupta Family Pilot Award in PSC Research:USD $50,000 for 1 year.
Autoimmune Liver Diseases Pilot Research Award:USD $20,000 for 1 year.
|Pinnacle Research Award in Liver Diseases:This is a basic science award that is intended to develop the potential of outstanding, young scientists and encourage research in liver physiology and disease. Applicants must be within the first six years of their first faculty appointment at the start of the award.|
Clinical, Translational and Outcomes Research Award:This award is intended to foster career development for individuals performing clinical research, translational research, or outcomes research in a liver-related area and who have shown commitment to excellence at an early stage of their research study. Applications in health disparities-related research are encouraged. Applicants must be within the first six years of their first faculty appointment at the start of the award. NOTE: Up to two applications per distinct department will now be accepted per single sponsoring institution.
Bridge Award:This supports investigators who have recently submitted an NIH R or other federally funded equivalent award and have received competitive scores on their proposal, but were not funded. Applicants must be at or below the rank of Associate Professor.
Pilot Research Award in Liver Diseases:This supports highly innovative research ideas that have a clear potential to produce high-impact results, but that have little or no preliminary data. Applicants must be faculty 3 years post appointment to at or below the Associate Professor Level.
Gupta Family Pilot Award in PSC Research: This award supports new, highly innovative PSC research ideas that focus on questions pertaining to the pathogenesis, diagnosis, and/or management of PSC in children and/or adults. Responsive projects will address highly innovative research ideas that have a clear potential to produce high-impact results, but that have little or no preliminary data to successfully compete for funding from other sources. Applicants must be at or below the rank of Associate Professor.
Autoimmune Liver Diseases Pilot Research Award:This provides supplementary funding during the pilot phase of basic, translational or clinical research projects in autoimmune liver disease (e.g. autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis) in preparation for future grant applications by the recipient. Applicants must be within the first six years of their first faculty appointment at the start of the award.
|December 2, 2021.|
|International||Paralyzed Veterans of America (PVA) Education Foundation Grants||Ranges between up to UST $10,000 to USD $50,000, depending on the topic category. All grants are for 12 months.||This funds educational projects that benefit and serve individuals with SCI/D, their families and caregivers. There are six topic categories for funding consideration, which are: Consumer, Caregiver, and Community Education; Professional Development and Education; Research Utilization and Dissemination; Assistive Technology; Consumer Guides; and Conferences and Symposia.|
Value: Ranges between up to UST $10,000 to USD $50,000, depending on the topic category. All grants are for 12 months.
|December 3, 2021.|
|International||ResMed Foundation Grants||Physician and Public Awareness Proposals: USD $10,000.|| Physician and Public Awareness Proposals: To further the awareness and knowledge of the inherent dangers of untreated SDB, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public.|
Clinical Research Proposals: The Foundation will consider proposals focused on the evaluation, diagnosis, treatment and management of sleep disordered breathing (SDB) and other respiratory disorders. Research areas of interest are also other morbidities that are associated with SDB which include cardiovascular disease, metabolic syndrome, diabetes and morbid obesity. The Foundation is also interested in the application of novel screening and diagnostic tools to identify more easily SDB/OSA, as well as new and better paradigms to improve patient adherence and compliance with positive airway pressure and ventilation-based treatment methods.
|Physician and Public Awareness Proposals: December 15, 2021.
|International||JDRF: Various Opportunities||Range from USD $150,000 per year for up to 3 or 5 years.||- Early-Career Patient-Oriented Diabetes Research Awards: Clinical researchers who have received their first faculty-level appointment less than 5 years before the submission date are eligible to apply for this award. Applicants must have an MD or||
- Innovative Awards: Deadline: October 14, 2021.
- Strategic Research Agreements
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY21 Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP)||Clinical Trial Award: Funding Level 1: Up to USD $750,000 total costs for up to 3 years; Funding Level 2: Up to USD $3M total costs for up to 4 years; Funding Level 3: Up to USD $6M total costs for up to 4 years.|
Focused Program Award: Up to USD $8M total costs for up to 4 years.
Translational Research Award: Up to USD $1.5M total costs for up to 3 years.
|Clinical Trial Award: Supports clinical trials for pharmacological (e.g., biologics, drugs) and non-pharmacological (e.g., devices, psychotherapy) interventions. |
Focused Program Award: Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal.
Translational Research Award: Supports the translation of promising research into clinical application (i.e., preclinical to clinical translation) and clinical care (i.e., implementation science).
Clinical Trial Award: Pre-Application: November 1, 2021; Application: December 16, 2021.
Focused Program Award: Pre-Application: November 1, 2021; Application: December 16, 2021.
Translational Research Award:Pre-Application: November 1, 2021; Application: December 16, 2021.
|International||ZOLL Foundation||Typically in the USD $10,000-$50,000 range.||This invites studies in the fields of resuscitation or acute critical care that aim to improve practices, prevent patient deterioration, reduce mortality and morbidity, or address some other aspect of enhancing care. Grant applicants should be newer researchers, ideally recommended by a more established investigator.||September 30, 2021; March 31, 2022.|
|International||American Academy of Sleep Medicine (AASM) Foundation: 2022 Strategic Research Grant||Category I: Up to USD $250,000 for 1-3 years|
Category II: Up to USD $100,000 for 1-2 years
Category III: Up to USD $50,000 for up to 1 year
|AASM is issuing four different Strategic Research Grant request for applications focused on the following research domains that will advance the field of sleep medicine and population sleep health.|
- AASM Strategic Plan Goals
- Continuous Positive Airway Pressure Treatment for Obstructive Sleep Apnea
- Hypopnea Scoring Criteria
- Treatment of Central Disorders of Hypersomnolence
|Letter of Intent: October 11, 2021.
Full Application (by invitation): March 14, 2022.
|International||BrightFocus Foundation National Glaucoma Research (NGR): Standard Awards||Up to USD $200,000 for up to 2 years.||The standard award provides significant funding for researchers who have already generated some amount of preliminary data, but are often required to demonstrate additional, significant progress before they can apply to governmental or industrial funding agencies.||October 26, 2021.|
|International||Morton Cure Paralysis Fund (MCPF) Research Grant||USD $5,000 to $75,000 for 1 year.||This funds activities that hold promise of identifying therapies (cures) for paralysis in humans. MCPF has particular focus of enabling scientists to develop the proof concept data necessary to apply for larger grants. The focus areas are: |
1. Understanding the effects of spinal cord injury at the cellular level, particularly with emphasis on that which determines apoptosis and/or prohibits regrowth.
2. Studying strategies to promote neuronal growth and survival, encourage the formation of synapses, enhance the production of myelin, restore conduction capabilities, or otherwise lead to restoration of the compromised circuitry in the acutely and chronically injured CNS.
3. Evaluating new therapies in clinical trial.
|October 31, 2021.|
|International||Mendez National Institute of Transplantation Foundation (MNITF) Research Grant Program (RGP)||USD $50,000 - $100,000 for 1 year.||These grants support innovative research to advance the science and practice of organ transplantation. Research in the following areas is considered: clinical outcomes in transplantation; donor screening technologies, immunogenetics, post-transplant monitoring, and advancements in regenerative medicine; new diagnostic and therapeutic paradigms; empowering patients with end-stage organ disease and transplant recipients through education to proactively manage their health and improve their long-term outcomes.||Letter of Intent: November 1, 2021.
Application (by invitation): December 15, 2021.
|International||Foundation for Physical Medicine & Rehabilitation (FPM&R) Mid-Career Research Grant||USD $25,000.||This is a short-term grant for research in topics related to the field of physical medicine and rehabilitation. Eligible applicants for grant include any physiatrist or faculty member in a division or department of physical medicine and rehabilitation who is at least 5 and not more than 20 years post-completion of a terminal degree and subsequent training program.||November 1, 2021.|
|International||Orthopaedic Research Society (ORS): ON/ORS Kick-Starter Grants||USD $10,000||This supports ORS members' research that focuses on an innovative approach in regenerative orthopaedics or that answers an important open question in that field. The topic is innovative scaffolds for the regeneration of musculoskeletal tissues.||November 2, 2021.|
|International||American Association for Cancer Research (AACR) AACR-Bristol-Myers Squibb Midcareer Female Investigator Grant||USD $225,000 for 3 years.||This supports mid-career female physician-scientists and researchers to conduct immuno-oncology research and to foster their career advancement toward becoming a senior investigator. Research projects may be translational and/or clinical in nature with a focus on immuno-oncology. Applicants must hold an appointment at the rank of Associate Professor. Applicants must be AACR Active members. Nonmembers interested in this grant opportunity must submit a satisfactory application for AACR Active membership by the application deadline.||November 11, 2021.|
|International||Cancer Research Institute (CRI) Technology Impact Award||Up to USD $200,000 for 12-24 months.||These grants aim to encourage collaboration between technology developers and clinical cancer immunologists and to generate the proof-of-principle of a novel platform technology in bioinformatics, ex vivo or in silico modeling systems, immunological or tumor profiling instrumentation, methods, reagents and assays, or other relevant technologies that can enable clinician scientists to generate deeper insights into the mechanisms of action of effective or ineffective cancer immunotherapies.||Letter of Intent: November 15, 2021.
Full Proposal (by invitation): March 15, 2022.
|International||Cancer Research Institute (CRI): Various Opportunities||Clinic and Laboratory Integration Program (CLIP) Grants: Up to $100,000 per year for 2 years.|
Technology Impact Award: Up to $200,000 for 12-24 months.
|Clinic and Laboratory Integration Program (CLIP) Grants: This provides funding for qualified scientists who are working to explore clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. The grant will support pre-clinical and translational research, which will provide information that can be directly applied to optimizing cancer immunotherapy in the clinic. |
Technology Impact Award: These grants aim to encourage collaboration between technology developers and clinical cancer immunologists and to generate the proof-of-principle of a novel platform technology in bioinformatics, ex vivo or in silico modeling systems, immunological or tumor profiling instrumentation, methods, reagents and assays, or other relevant technologies that can enable clinician scientists to generate deeper insights into the mechanisms of action of effective or ineffective cancer immunotherapies.
|Clinic and Laboratory Integration Program (CLIP) Grants: Letter of Intent: December 1, 2021; Full Proposal (by invitation): March 1, 2022.
Technology Impact Award: Letter of Intent: November 15, 2021; Full Proposal (by invitation): March 15, 2022.
|International||Bayer Hemophilia Awards Program (BHAP): Various Opportunities||Clinical Research Award:>/b> Up to USD $75,000 for 1 year.|
Basic Research Award: Up to USD $75,000 for 1 year.
Patient Engagement Award: Up to USD $25,000 for 1 year.
|Clinical Research Award:>/b> Provides funds to undertake a clinical research project in the bleeding disorders field. |
Basic Research Award: Provides funds to undertake a basic research project in the bleeding disorders field.
Patient Engagement Award: Provides funds to support efforts in the field of patient engagement, education and advocacy within hemophilia. It recognizes the essential role of nurses, allied healthcare professionals and caregivers in the care of patients with hemophilia.
|Letter of Intent: November 30, 2021.
Full Proposal (by invitation): February 2022.
|International||Sigma Foundation for Nursing: Nursing Research Grants||Small Grants: Up to USD $5,000 for up to 1 year.|
Alpha Eta Collaborative Research Grant: Up to USD $5,000 for up to 1 year.
Canadian Nurses Foundation Collaborative Grant: Up to USD $5,000 for up to 1 year.
Council for the Advancement of Nursing Science: Up to USD $5,000.
Rosemary Berkel Crisp Research Award: Up to USD $5,000 for up to 1 year.
|Small Grants:Projects that focus on marginalized populations are strongly encouraged and will be given preference, other qualifications being equal.|
Alpha Eta Collaborative Research Grant:Available to Chi Omicron At-Large Chapter, Chi Xi At-Large Chapter, and/or Tau Lambda At-Large Chapter members for a new research project in Africa
Canadian Nurses Foundation Collaborative Grant:Supports research that advances the practice of nursing with an emphasis on nursing care issues.
Council for the Advancement of Nursing Science:Proposals for clinical, educational or historical research, including plans for broadly disseminating the research findings, may be submitted for the grant.
Rosemary Berkel Crisp Research Award:Supports nursing research in the critical areas of women's health, oncology, and pediatrics.
|December 1, 2021.|
|International||ResMed Foundation: Physician and Public Awareness||USD $10,000.||This is to further the awareness and knowledge of the inherent dangers of untreated sleep disordered breathing, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public. Only programs that have wide outreach to a significant clinical or public population base will be considered.||December 15, 2021.|
|International||American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNSF): CORE Grants Various Opportunities||AAO-HNSF Maureen Hannley Research Grant: USD $50,000 for 1 year.|
AAO-HNSF Health Services Research Grant: USD $10,000 for 1 year.
AAO-HNSF Bobby R. Alford Endowed Research Grant: USD $30,000 for 1 year.
American Rhinologic Society (ARS) New Investigator Award:USD $40,000 total for up to 24 months.
ARS Friends in Research Award: USD $25,000 total for up to 2 years.
ARS Consortium Award:USD $50,000 per year for up to 3 years.
ARS Women in Rhinology Research Grant:USD $10,000 total for up to 2 years.
|AAO-HNSF Maureen Hannley Research Grant: Designed to fill "research gaps" identified by the AAO-HNSF clinical practice guideline panels. |
AAO-HNSF Health Services Research Grant: Proposed projects should be related to any area of otolaryngology-head and neck surgery and must have direct or potential clinical significance for patients seen by otolaryngologist-head and neck surgeons.
AAO-HNSF Bobby R. Alford Endowed Research Grant: Supports innovative research in the specialty and help facilitate the career development of young investigators. Applicants may be independent practitioners or practitioners affiliated with academic or similar institutions who have completed their residency within the past 7 years.
American Rhinologic Society (ARS) New Investigator Award: Supports basic, translational, or clinical research projects in rhinology.
ARS Friends in Research Award: Both early and mid-career investigators are encouraged to apply. Supports basic, translational, or clinical research projects in rhinology.
ARS Consortium Award: Supports inter-institutional basic, translational, or clinical research projects in rhinology. Any group of three or more ARS members at different institutions may apply.
ARS Women in Rhinology Research Grant: Supports basic, translational, clinical, health services, or outcomes research projects in rhinology with potential to clarify the role of artificial intelligence in sinonasal computed tomography. Proposed research must include at least one female investigator as either the Principal Investigator or a co-investigator.
|Letters of Intent: December 17, 2021.
Applications: January 18, 2022.
|International||Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Mitzi & William Blahd, MD, Pilot Research Grant||USD $25,000 for one year.||The pilot research grant is designed to help a basic or clinical scientist in the early stages of their career conduct research that may lead to further funding. Applicant must be no more than five years post training (most recent training; training includes residency, MD/PhD training, professional school, graduate school, post doc, or fellowship).||January 6, 2022.|
|International||Intuitive Foundation Clinical Research Grants for Robotic-Assisted Surgery||Up to USD $60,000 per project for up to 1 year.||The purpose of these grants is to support clinical research at non-profit institutions worldwide focused on the field of robotic-assisted surgery. Successful proposals will study important questions related to surgical care and patient outcomes.||Letter of Intent (LOI): January 7, 2022.
Full Application (by invitation): April 1, 2022.
|International||Radiological Society of North America (RSNA) Research Seed Grant||Up to USD $40,000 for a 1 year project.||The seed grant is for investigators to define objectives and test hypotheses in preparation of major grant applications to corporations, foundations and governmental agencies. Supports projects in any area of research related to the radiologic sciences, from hypothesis-driven basic science and clinical investigations to topics such as drug, device, and therapy development; comparative effectiveness; evidence-based radiology; ethics and professionalism; quality improvement; clinical practice efficiency; and imaging informatics.||January 18, 2022.|
|International||International Society for the Study of the Lumbar Spine (ISSLS) Research Grant||USD $20,000 per year.||This is to promote research in the lumbar spine. The research proposal can be in basic science, biomechanics or the clinical field. The principal investigator must be less than 45 years of age. At least one investigator must be an ISSLS member.||28-Feb-22|
|International||Pfizer Global Medical Grants (GMG): COVID-19 Vaccine Grants||--||COVID-19 Vaccine General Research (now open): Pfizer is accepting COVID-19 general research grant requests that address the following areas: Studies evaluating COVID-19 burden of disease and sero-epidemiological surveys among specific populations.|
- Epidemiology studies evaluating direct & indirect impact, including modeling approaches, of Pfizer's vaccine particularly in specific patient populations.
- Studies measuring the impact of efforts to overcome vaccine hesitancy and enhance vaccine uptake.
COVID-19 Vaccine Independent Medical Education (coming soon): Optimize the prevention of COVID-19 by:
- Increase awareness of the risk of COVID-19 for all ages and racial and ethnic groups.
- Increase the understanding, and familiarity with, the proper storage, handling and administration of Pfizer's vaccine.
|Vaccine General Research: Rolling submission.
Independent Medical Education: TBA
|International||Alzheimer's Association: International Research Grant Program||--||Multiple Opportunities||Various
|International||Solving Kids Cancer (SKC): Therapeutic Development Initiative (TDI) - Funding for High-Impact Pediatric Cancer Research||$50,000 to $500,000 USD for up to 2 years.||The TDI of SKC only supports clinical research.||Preliminary Proposal Deadline: Ongoing|
|International||Össur Orthopaedic Research Grant Program||--||This provides funding for scientific inquiry in the areas of lower extremity biomechanics, dynamic/active rehabilitation, ortho biologics, functional bracing, clinical patient outcomes, and, related healthcare economics.||Rolling Deadline|
|International||Gateway for Cancer Research (GFCR): Various Opportunities||GFCR Grant Program: USD $200,000 to $1.5 million for 2-5 years|
GFCR Integrative Program:USD $200,000 to $1.5 million for 2-5 years.
SIO / Gateway Integrative Research Grant Program: Value: USD $200,000 to $1.5 million for 2-5 years.
GFCR Decentralized (DCTI) Grant Program: Not specified.
|Gateway funds Phase I and II patient-centered cancer clinical trials that have the potential to shift the paradigm for standard of care, focusing on the following priority research areas: Biomarkers/Molecular Markers (genomic or proteomic); Gene Therapy; Histology Agnostic/Basket Trial; Immunotherapy; Targeted Therapies. Focus is on the following therapeutic areas: New Investigational Therapies; Novel Use or Approach; Precision Medicine; Integrative Medicine.|
GFCR Grant Program: Funds early phase clinical trials for cancers of all types at renowned institutions around the world.
GFCR Integrative Program: Funds integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment.
SIO / Gateway Integrative Research Grant Program: Funds integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment.
GFCR Decentralized (DCTI) Grant Program: Leverages site-less, technology-informed trials, with the objective of bringing clinical trials directly to patients doorsteps.
|GFCR Grant Program: Rolling Deadline
GFCR Integrative Program:Rolling Deadline
SIO / Gateway Integrative Research Grant Program: Rolling Deadline
GFCR Decentralized (DCTI) Grant Program: December 31, 2021.
|International||Aesculap Implant Systems Investigator-Initiated Study Program (IIS)||--||This supports researchers interested in conducting studies of their own design, which promotes the advancement of medical and scientific knowledge related to Aesculap's products and therapeutic areas of focus: Neurosurgery; Surgical Technologies; Closure Technologies; Orthopaedics; Spine; Biologics.||Continuous intake|
|International||Bausch + Lomb Grants||--||Educational Grants: These contribute to the improvement of patient care and advances in the use of healthcare products. Grand-rounds, lectures, symposiums and workshops are funded to educate medical students, university faculty, physicians, nurse practitioners, optometrists, ophthalmologists, allied health professionals, optical research scientists and associations of optometry and ophthalmology about improvements in ocular health.|
Independent Research Grant: These empower the global research community to develop new treatments and technological advancements in ocular health. Research Grants have been funded by to improve consumers standard of care, efficacy, patient satisfaction, safety and vision performance.
|Rolling submission. Allow 6-12 weeks for proposal review and decision.|
|NIH||NIH Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies||--||National Institute of Allergy and Infectious Diseases (NIAID) is interested in the development and optimization of next generation methodologies for HIV-1 drug resistance (DR) mutation detection and reporting. Strategies applicable to low and middle income countries as defined by the World Bank are especially encouraged.|
National Institute on Drug Abuse (NIDA) is interested in the following areas: Feasibility of self-administered, cost effective, and potential for mail-in testing and follow up through mobile technologies targeting substance-using populations living with HIV; Development of technologies that allow sensitive and rapid read out of drug resistance; Plans for post-administering surveys to assess rates of access, acceptability (stigma and ethical concerns), accuracy, and treatment outcomes; Technologies that are easily adaptable for implementation in homeless shelters, community clinics, criminal justice, and emergency department settings.
|This notice applies to due dates on or after September 5, 2021 and subsequent receipt dates through May 7, 2024.|
|NIH||NIH Notice of Special Interest (NOSI) HIV/AIDS in the Era of COVID-19: When Pandemics Collide||--||This is to communicate special interest in epidemiology investigations to quantify the impact of the COVID-19 pandemic on HIV prevention, incidence, transmission, and outcomes. This NOSI encourages research on the impact and strategies needed to adapt the HIV/AIDS response through agile and innovative support of prevention and care and the maintenance of sustained HIV viral suppression during the COVID-19 pandemic.||This notice applies to due dates on or after September 7, 2021 and subsequent receipt dates through May 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities||--||This NOSI encourages applications that address dimensions of access, acceptance and uptake of CDC-recommended vaccines among infants, children, adolescents, pregnant and lactating women, and persons with disabilities, especially among populations who are underserved or experience health disparities.||This notice applies to due dates on or after September 8, 2021 and subsequent receipt dates through May 8, 2024.|
|NIH||NIH Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)||--||The primary objective is to move Digital Therapeutics (DTx) to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for Substance Use Disorders (SUDs). Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.||September 8, 2021; January 10, 2022; September 8, 2022; January 10, 2023; September 8, 2023; January 10, 2024.|
|NIH||Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention|
- PA-18-861 (R03 - Clinical Trial Optional)
|--||The purpose is to encourage research grant applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination.||Standard dates apply until January 8, 2022 (R03).|
|NIH||Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2||--||This NOSI encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate:|
- SARS-CoV-2 candidate vaccines
- non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19
- therapeutic approaches to treat COVID-19
|Applications will be accepted once a month through September 14, 2021.|
|NIH||NIH Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease and Related Dementias (AD/ADRD)||--||These support applications to address psychological and interpersonal mechanisms driving adherence to behaviors or lifestyle changes relevant to prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).|
PAR-21-207 (R01 Clinical Trial Optional): Specifically supports ancillary studies to ongoing, early- to late-stage clinical intervention trials. Ancillary studies should provide the opportunity to explore novel psychological and interpersonal mechanisms by collecting new data from participants enrolled in the ongoing parent study. Deadlines: September 15, 2021; January 26, 2022.
PAR-21-207 (R01 Clinical Trial Optional): September 15, 2021; January 26, 2022.
|NIH||NIH Identification of Positive Valence System Related Targets for Novel Suicide Prevention Approaches: Various Opportunities||--||This solicits applications for research projects that will advance translational research to better understand risk and resilience for suicide in the context of the NIMH Research Domain Criteria (RDoC) framework, specifically the Positive Valence Systems (PVS) domain, and lead to novel interventions. |
PAS-21-215 (R21 Clinical Trial Optional): For exploratory, smaller scope, highly-innovative projects. Deadline: October 16, 2021.
PAS-21-216 (R01 - Clinical Trial Optional): For projects that require more time, a more flexible budget, and are larger in scope. Deadline: October 5, 2021.
|PAS-21-215 (R21 Clinical Trial Optional): October 16, 2021.
PAS-21-216 (R01 - Clinical Trial Optional): October 5, 2021.
|NIH||NIH Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery: Various Opportunities||--||This invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. |
- PAR-21-349 (R01 Basic Experimental Studies with Humans Required): Types of projects include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolation. Applications should not propose a goal of clinical outcomes or products.
- PAR-21-350 (R01 Clinical Trials Not Allowed): For applications that propose studies including model animal research or observational studies involving humans. Both animal model and human subjects research projects are welcome; however, clinical trials are not allowed.
- PAR-21-352 (R01 Clinical Trial Required): Types of projects include mechanistic studies that are classified as clinical trials. Types of studies include clinical trials that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.
|June 21, 2022; June 21, 2023; June 21, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to improve use of Evidence-Based Practices for heart, lung, blood, and sleep (HLBS) conditions||--||National Heart, Lung, and Blood Institute (NHLBI) encourages applications that recognize the importance of cultural context, patterns of behavior change, and motivators for change across decision-making levels, including individuals (e.g., patients, parents, clinicians, others), groups, healthcare systems and/or communities.||This notice applies to due dates on or after October 5, 2021 and subsequent receipt dates through September 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research||--||The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the US. Applications examining all areas of National Institute on Drug Abuse (NIDA)-supported research addressing the causes, consequences, treatment, and prevention of drug use, misuse, and addiction are encouraged. Projects should be conducted through newly formed or well-established partnerships between an investigator in a US-based institution and a scientist working in another country.||This notice applies to due dates on or after October 5, 2021 and subsequent receipt dates through September 8, 2024.|
|NIH||NIH Dementia Care and Caregiver Support Intervention Research||--||R01 Research Project Grant - Clinical Trial Required: This solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) and of those providing their care.|
R61/R33 - Clinical Trial Required: This will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings. This will support Stage I or Stage III pilot research to test the feasibility of implementing and integrating interventions (R61 phase) that, if successful, can transition to an R33 phase (Stage IV) for implementation of large pragmatic trials.
|October 7, 2021; February 10, 2022; October 11, 2022; February 10, 2023; October 10, 2023; February 13, 2024.|
|NIH||NIH NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)||--||This is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies.||October 13, 2021; February 9, 2022; June 9, 2022; October 11, 2022; February 9, 2023; June 9, 2023; October 10, 2023; February 9, 2024.|
|NIH||NIH HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed)||--||The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards. The limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application.||October 13, 2021, June 9, 2022, October 11, 2022, June 9, 2023, and October 10, 2023.|
|NIH||NIH HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)||--||The goal of this funding opportunity announcement (FOA) is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic / pharmacodynamic (PK/PD) studies are also responsive. This FOA is not specific for any one or group of pain conditions.||October 13, 2021, June 9, 2022, October 11, 2022, June 9, 2023, and October 10, 2023.|
|NIH||Single-Site Investigator-Initiated Clinical Trials (R61/R33)||--||This grant supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies.||October 14, 2021; February 11, 2022; June 10, 2022|
|NIH||Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24)||--||This grant supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies.||October 14, 2021; February 11, 2022; June 10, 2022|
|NIH||NIH National Institute of Mental Health (NIMH) Clinical Trial Funding Opportunity Announcements (FOAs): Various Opportunities||--||NIMH solicits clinical trial applications through a series of FOAs that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials.|
PAR-21-129: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)
PAR-21-130: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)
PAR-21-131: Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)
PAR-21-132: Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)
PAR-21-134: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)
PAR-21-135: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
PAR-21-136: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
PAR-21-137: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
|October 15, 2021; February 15, 2022; June 15, 2022; October 14, 2022; February 15, 2023; June 15, 2023; October 17, 2023; February 15, 2024.|
|NIH||NIH Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)||--||This encourages theoretically-driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. Other outcomes of interest include a reduction in negative sequalae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.||October 16, 2021; February 16, 2022; June 16, 2022; October 16, 2022; February 16, 2023; June 16, 2023; October 16, 2023.|
|NIH||National Cancer Institute (NCI) Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)||--||This grant supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities.||October 20, 2021; February 22, 2022; June 21, 2022|
|NIH||NIH Translational Neural Devices (UG3/UH3 - Clinical Trial Optional)||--||This encourages investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.||October 20, 2021; February 18, 2022; June 20, 2022; October 18, 2022; February 21, 2023; June 19, 2023; October 18, 2023; February 20, 2024.|
|NIH||Neural Regulation of Cancer|
- PAR-19-353 (R01 Clinical Trial Not Allowed)
- PAR-19-354 (R21 Clinical Trial Not Allowed)
|--||These opportunities encourage collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer.||October 21, 2021; May 27, 2022|
|NIH||NIH Biomarkers for Diabetic Foot Ulcers through the Diabetic Foot Consortium (R61/R33 Clinical Trial Not Allowed)||--||This is to promote the development of prognostic, monitoring, and diagnostic biomarkers for diabetic foot ulcers that can be used in clinical trials and patient care. This initiative will support early analytical and clinical validation of biomarkers through a phased award to encourage innovative research. The initiative will leverage the resources of the Diabetic Foot Consortium to facilitate the access to well-characterized patients and high-quality human samples.||November 3, 2021.|
|NIH||NIH Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)||--||This encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.||November 8, 2021; March 7, 2022; November 8, 2022; March 7, 2023; November 5, 2023; March 7, 2024.|
|NIH||NIH Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional)||--||This supports research to understand and respond to the new challenges in treating drug addiction and overdose, introduced by the presence of fentanyl and its analogs (fentanyls) in illicit drug supplies. The research may include preclinical, clinical, epidemiological or even post-mortem studies. Studies should have high significance in order to quickly yield improvements in understanding and to provide effective responses to the problems caused by illicit fentanyls.||November 11, 2021.|
|NIH||Research on Current Topics in Alzheimer's Disease and Its Related Dementias |
- PAR-19-070 (R01 Clinical Trial Optional)
- PAR-19-071 (R21 Clinical Trial Not Allowed)
|--||This invites applications proposing research on current topics in Alzheimer's disease and its related dementias. Further information on the high-priority topics of interest will be announced through a series of notices that are linked at the top of the funding opportunity websites.||November 12, 2021.|
|NIH||Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)||--||This invites exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.||17-Nov-21|
|NIH||Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)||--||This invites Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. A Cooperative Agreement means that after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities.||17-Nov-21|
|NIH||Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)||--||This invites Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. A Cooperative Agreement means that after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities.||17-Nov-21|
|NIH||Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)||--||The intent of this funding is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies.||November 17, 2021; March 17, 2022; July 19, 2022; November 7, 2022|
|NIH||NIH Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and Persistence in People Living with HIV||--||This solicits research to better understand the epidemiology and biology of oral HPV infection, its acquisition and persistence, in people living with HIV and elucidate the initial mechanisms related to HPV-associated oral and oropharyngeal cancers and warts in the context of HIV. |
RFA-DE-22-003 R01 Clinical Trial Not Allowed
- RFA-DE-22-004 R21 Clinical Trial Not Allowed
|November 18, 2021.|
|NIH||New Models of Integrated HIV/AIDS, Addiction, and Primary Care Service|
- PAR-20-273 (R01 Clinical Trial Required)
- PAR-20-274 (R34 - Clinical Trial Optional)
|--||This supports the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services.|
- PAR-20-273 (R01 Clinical Trial Required): This seeks applications that will test comprehensive service delivery models. Applicants needing to develop, refine, and/or test key components of such a model are encouraged to apply to the companion R34.
- PAR-20-274 (R34 - Clinical Trial Optional): The R34 grant mechanism is intended to encourage planning research by providing support for the initial development of a clinical trial or research project.
|November 18, 2021; August 11, 2022; November 18, 2022; August 11, 2023|
|NIH||Emotion Regulation, Aging and Mental Disorder|
- PA-19-094 (R01 Clinical Trial Not Allowed)
- PA-19-095 (R21 Clinical Trial Not Allowed)
|--||This encourages applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. Applicants with preliminary data may wish to apply using the R01 mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies utilizing existing data may wish to apply using the R21 mechanism.||Standard dates apply until January 8, 2022.|
|NIH||Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (R21 Clinical Trial Not Allowed)||--||This supports projects that utilize open-access data available via the Bioinformatics Resource Centers (BRCs), alone or in combination with other datasets, to address knowledge gaps in basic and/or clinical research in infectious diseases. Projects focused on influenza, Mycobacterium tuberculosis (TB), antimicrobial resistance and malaria are encouraged although projects based on other pathogens relevant to National Institute of Allergy and Infectious Diseases will be supported.||Standard dates apply until January 8, 2022.|
|NIH||Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities||--||This seeks research strategies and interventions to address vaccine hesitancy, uptake, and implementation among populations who experience health disparities in the US. Research is needed to understand and address misinformation, distrust, and hesitancy regarding vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), and herpes zoster) among adults in the US and territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities and chronic medical conditions.||This notice applies to receipt dates through January 8, 2022.|
|NIH||Bioengineering Research Grants (BRG)|
- PAR-19-158 (R01 Clinical Trial Not Allowed)
- PAR-19-159 (R01 Clincal Trial Required)
|--||The purpose is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice.||Standard dates apply until January 8, 2022.|
|NIH||NIH Patient Activation for Self-Management of Chronic Conditions (R01 Clinical Trial Optional)||--||This encourages grant applications that address the influence of patient activation on self-management of chronic conditions.||New Applications: February 5, 2022; June 5, 2022; February 5, 2023; AIDS Applications: September 7, 2021; May 7, 2022; September 7, 2022; May 7, 2023.|
|NIH||NIH Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)||--||The National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial.||February 11, 2022; June 10, 2022; October 11, 2022; February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; October 11, 2024.|
|NIH||NIH HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)||--||This supports high priority research at the intersection of HIV and substance use. It is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research.||February 15, 2022; August 15, 2022; February 15, 2023; August 15, 2023; February 15, 2024.|
|NIH||NIH Tobacco Regulatory Science (R01 Clinical Trial Optional)||--||This supports biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).||February 15, 2022, July 14, 2022, February 14, 2023.|
|NIH||NIH Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required)||Up to USD $450,000 for up to 3 years.||This is pilot projects to evaluate the preliminary effectiveness of interventions targeting preschool attention deficit hyperactivity disorder (ADHD) symptoms and impairments. An emphasis is placed on studies that take a theory-driven, empirical approach to developing and testing interventions intended to impact current ADHD symptoms and impairments and/or prevent or forestall the emergence of co-occurring disorders or additional ADHD-related impairments.||March 1, 2022.|
|NIH||NIH Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)||--||The National Institute on Drug Abuse (NIDA) CEBRA fosters highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research.||March 8, 2022; August 10, 2022; March 8, 2023; August 10, 2023; March 8, 2024.|
|NIH||Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed)||--||The purpose is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.||Standard dates apply until May 8, 2022.|
|NIH||NIH Dissemination and Implementation Research in Health||--||This supports innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ("de-implement") the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.|
- PAR-19-274 (R01 Clinical Trial Optional)
- PAR-19-275 (R21 Clinical Trial Optional)
-PAR-19-276 (R03 Clinical Trial Not Allowed)
|Standard dates apply until May 8, 2022.|
|NIH||NIH Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)||--||This supports exploratory studies developing or using novel tools or technologies or testing novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including neuroHIV) in the context of Substance Use Disorders (SUDs). This initiative focuses on exploration and characterization of signaling pathways that are involved in CNS HIV establishment and expansion. This promotes research to investigate the underlying molecular mechanisms by which HIV infection is initiated, established, and maintained in the CNS and to determine how addictive substances modulate HIV infection, latency and the size and persistence of CNS HIV reservoirs.||July 14, 2022; September 7, 2022.|
|NIH||Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)||--||The purpose of this grant is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval.||Applications will be accepted on a rolling basis, expiring on September 1, 2022.|
|NIH||Notice of Special Interest (NOSI): Research in the Emergency Setting||--||This notice invites basic, translational and clinical research and career development programs that effect all areas of emergency medical care, including injury and trauma. Please see opportunity details for the lists of NIH Institutes and Centers and associated funding opportunity announcements to use for submission of an application in response to this NOSI.||This notice applies to receipt dates through September 8, 2022.|
|NIH||NIH Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children||--||This highlights interest in research to understand the mental health impact of the COVID-19 pandemic on school-aged children, specifically ages 3 - 12. Particularly, NIH is interested in the potential impact of primary instruction settings disruptions (e.g., pre-school, elementary school) on the mental health, cognitive, social, and emotional development of children.||This notice applies to subsequent receipt dates through September 8, 2022.|
|NIH||NIH National Library of Medicine Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)||--||The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. The scope of NLM's interest in these research domains is broad, with emphasis on new methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, reusable approaches to discovery, curation, analysis, organization and management of health-related digital objects.||Standard dates apply until September 8, 2022|
|NIH||NIH Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)||--||This encourages innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness.||October 5, 2021; February 5, 2022; June 5, 2022; October 5, 2022; February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024.|
|NIH||NIH Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)||--||This supports applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).||June 7, 2022; October 7, 2022; June 7, 2023; October 9, 2023; June 7, 2024; October 8, 2024|
|NIH||NIH Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)||--||This supports studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses against infectious agents, or of the roles played by complement in the development of immune-mediated pathogenic responses following infection. The results of such studies will inform the development of adjuvants and vaccine candidates or therapeutics that target complement components.||This notice applies to subsequent receipt dates through January 7, 2023.|
|NIH||Co-infection and Cancer|
- PAR-20-062 (R01 Clinical Trial Not Allowed)
- PAR-20-061 (R21 Clinical Trial Not Allowed)
|--||The purpose is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents - either concurrently or sequentially- and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.||Standard dates apply until January 8, 2023|
|NIH||Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)||--||This encourages projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. This is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.||Standard dates apply until January 8, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Promoting Pain Research Within the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Mission Areas||--||This NOSI invites research applications that focus on improving the understanding of mechanisms of acute and chronic pain, and enhancing knowledge that will help better prevent, manage and reduce pain and improve health equity of all populations suffering from acute or chronic pain caused by rheumatic, autoinflammatory, musculoskeletal, and skin diseases and conditions within the NIAMS mission.||This notice applies to due dates on or after November 5, 2021 and subsequent receipt dates through January 10, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration||--||The specific research objectives of this NOSI are to rapidly expand the knowledge base on acute and long-term neurological and neurocognitive sequelae of COVID-19. NIA encourages investigator-initiated new and resubmission applications for research activity codes (i.e., R21, R01, R03) to address significant questions about the neurological and neurocognitive impacts of COVID-19 infection in aging and the interaction in older adults of COVID-19 with comorbid conditions, including Alzheimer's disease (AD) and AD-related dementias (ADRD).||This notice applies to subsequent receipt dates through May 7, 2023.|
|NIH||Notice of Special Interest (NOSI): Adopting Techniques and Tools Developed from the BRAIN Initiative Toward National Institute of Mental Health (NIMH) Strategic Research Priorities||--||NIMH is encouraging the submission of applications proposing to use the following types of tools/technologies developed in the BRAIN Initiative:|
- Technologies that enable causal in vivo behavioral neuroscience experimental designs to probe functions of neural circuits implicated in the above-mentioned behavioral domains
- Technologies that analyze and manipulate complex circuits with a goal to provide comprehensive circuit diagrams
- Technologies that monitor neural activity and in vivo behaviors
- Interventional tools
- Technologies that allow examination of developmental time course and/or sex differences in mental health-relevant circuit function
- Computational modeling approaches and data analysis
|This notice applies to receipt dates through May 8, 2023.|
|NIH||Notice of Special Interest (NOSI): Research on Rehabilitation Needs Associated with the COVID-19 Pandemic||--||The purpose of this NOSI is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation:|
- Encourage research to address the rehabilitation needs of survivors of COVID-19
- Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions
- Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities
|This notice applies to receipt dates through May 8, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)||--||This supports research that improves our understanding of the behavioral, social, and economic effects of the pandemic and to enhance our ability to control its spread. These effects will likely be particularly acute for NIH-designated health disparity populations , and other COVID-19 vulnerable groups including older adults, who have experienced higher rates of COVID-19 infection, who in some cases rely on the efforts of paid and unpaid care partners, and who may have additional barriers to accessing the medical system itself. Further, middle-aged and older frontline healthcare and essential workers and their families face unique risks of exposure to both infection and other health-related outcomes by virtue of their employment.||This notice applies to receipt dates May 8, 2023.|
|NIH||Occupational Safety and Health Research (R01) ||--||The purpose is (1) to develop an understanding of the risks and conditions associated with occupational diseases and injuries, (2) to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and (3) to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries.||Standard dates apply until November 18, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes||--||This supports applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes. These include, but are not limited to:|
- Investigation of aging trajectories associated with specific cancer treatments and identification of cancer survivors at risk for an "accelerated aging" phenotype;
- Examination of the effects of specific cancer treatments on aging biology that may alter aging trajectories or aging outcomes;
- Development and/or validation of tools, technologies, measures, or techniques for the identification of late-emerging effects and aging phenotypes among cancer survivors;
- Use of old and young animal models to determine the effects of established and newer cancer therapies on aging endpoints;
- Development and/or testing of interventions designed to prevent, mitigate or reverse the adverse aging-related effects of cancer and cancer treatments; and
- Development and/or testing of interventions focused on models and processes of care delivery to intervene at the intersection of cancer treatment and aging.
|This notice applies to receipt dates through January 7, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers||--||This supports the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the ultimate goal of improving early detection and risk assessment for abdominal cancers. This encourages applications proposing multi-institutional collaborative AI development approaches such as federated learning, which distributes the models to data-owners and aggregates the results without sharing the actual data.||This notice applies to subsequent receipt dates through January 8, 2024.|
|NIH||NIH Priority HIV/AIDS Research within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 Clinical Trial Optional) ||--||This seeks to stimulate HIV/AIDS research within the mission of the NIDDK that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.||Standard AIDS dates apply until January 8, 2024.|
|NIH||NIH Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R21 Clinical Trial Not Allowed) ||--||This is for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Potential topics could address multiple overarching priorities.||Standard AIDS dates apply until January 8, 2024.|
|NIH||Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)||--||This supports investigator-initiated clinical that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health.||Standard dates apply until January 8, 2024.|
|NIH||Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders||--||National Heart, Lung, and Blood Institute (NHLBI) seeks to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions.||This notice applies to receipt dates through January 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition||-||This encourages applications in high-priority research areas related to pediatric health care transition for youth with chronic physical/medical conditions or intellectual/developmental disabilities. Research applications that will advance our understanding of promising practices designed to facilitate successful health care transitions (HCT) from pediatric to adult care settings as well as barriers and facilitators to such transition are encouraged.||This notice applies to subsequent receipt dates through January 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Telehealth in Cancer Care||--||This supports investigator-initiated applications for conducting research on the use of telehealth in cancer-related care. Studies focused on populations that experience inequities in access to care and have worse cancer outcomes compared to the general population are strongly encouraged.||This notice applies to subsequent receipt dates through March 8, 2024.|
|NIH||NIH Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes||--||National Institute of Mental Health (NIMH) seeks applications to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus and intensity/burden.|
PAR-21-211 (R34 Clinical Trial Required): This supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials.
PAR-21-210 (R01 Clinical Trial Required): This supports fully-powered, definitive effectiveness studies focused on post-acute phase interventions
|Standard dates apply until March 17, 2024.|
|NIH||NIH Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)||--||This supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community.||Standard dates apply until May 8, 2024.|
|NIH||NIH NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)||--||This supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data.||Standard dates apply until May 8, 2024.|
|NIH||Notice of Special Interest (NOSI) regarding the Use of Human Connectome Data for Secondary Analysis||--||This encourages secondary analyses of data from the Human Connectome Project (HCP), including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease.||This notice applies to receipt dates through May 8, 2024.|
|NIH||NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): Various Opportunities||Up to USD $50,000 per year for up to 2 years.|| PA-21-231 (R03 Basic Experimental Studies with Humans Required): This is for basic science experimental studies involving humans. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. |
PA-21-221 (R03 Clinical Trial Required): This supports clinical trials that fall within the NICHD mission.
|Standard dates apply until May 8, 2024.|
|NIH||NIH Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment||--||The purpose is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. Each partnership should include at least one academic and one industrial organization.|
PAR-21-166: R01 - Clinical Trial Not Allowed
PAR-21-206: R01 - Clinical Trial Optional
|Standard dates apply until May 8, 2024.|
|NIH||NIH Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity: Various Opportunities||--||The purpose of these Funding Opportunity Announcements (FOAs) is to lay the groundwork for developing interventions at the network/circuit level that might be used as potential treatments for cognitive, affective, or social deficits in psychiatric disorders. These FOAs support projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing.|
PAR-21-175 (R01 Clinical Trial Optional)
PAR-21-176 (R21 Clinical Trial Optional)
|Standard dates apply until May 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health||--||This calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels.||This notice applies to subsequent receipt dates through June 8, 2024.|
|NIH||Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)||--||This NOSI seeks to support investigation into the factors and molecular mechanisms that address the heterogeneity dictated by the host resilience. Research on general host responses to injurious challenges and their effects on lung function as well as mechanisms that impact susceptibility to ARDS is not considered to be responsive to this announcement.||This notice applies to receipt dates through July 5, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning||--||This encourages grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. National Institute on Drug Abuse (NIDA) is interested in applications that make use of existing data, such as epidemiologic cohorts, clinic cohorts and longitudinal follow-up studies of interventions, as well as other publicly available sources of data including data warehouses and commercial data sources. Substance use should be a key component of any research supported by this NOSI.||This notice applies to subsequent receipt dates through September 7, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19||--||National Institute on Drug Abuse (NIDA) is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.||This notice applies to due dates through September 7, 2024.|
|NIH||Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection||--||This NOSI encourages research to understand: |
- The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection.
- The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana.
- The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer.
|This notice applies to due dates through September 8, 2024.|
|NIH||NIH Neuromodulation/Neurostimulation Device Development for Mental Health Applications||--||This encourages applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently FDA-approved or cleared.|
- R01 Clinical Trial Not Allowed: For applicants who seek to propose a larger project. Applicants who seek to establish proof-of-concept should respond to the companion R21.
|Standard dates apply until January 8, 2025.|
|NIH||NIH Basic Research in Cancer Health Disparities||--||This encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities.|
- R01 Clinical Trial Not Allowed: These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities.
- R21 Clinical Trial Not Allowed: This provides support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities.
- R03 Clinical Trial Not Allowed These small research grants will support projects on cancer health disparities that can be carried out in a short period of time with limited resources.
|Standard dates apply until September 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood||--||This supports support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitionary phases, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years), and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitionary phases.||This notice applies to due dates on or after October 5, 2021 and subsequent receipt dates through June 5, 2026.|
|NIH||NIH Parent Announcements||--||NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)|
Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) (PA-20-184)
Research Project Grant (Parent R01 Clinical Trial Required) (PA-20-183)
NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) (PA-20-200)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) (PA-20-195)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) (PA-20-194)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required) (PA-20-196)
|Standard dates apply unless otherwise stated.|